Domenica M. Rubino, ENDO 2021: Findings from the STEP 4 Study
It was a pleasure to talk to Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA, US) around the effect of once-weekly semaglutide on weight loss maintenance in overweight or obese adults.
‘Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4).‘ (PRESENTATION NUMBER: OR02-3) was presented at the ENDO 2021 Virtual Annual Meeting, March 20 – 23, 2021.
Questions
- What are the current unmet needs in the management of adults with obesity? (0:13)
- What was already known about the weight loss benefits of semaglutide in people with obesity? (2:13)
- What were the aims and design of the STEP 4 study, and what were the findings? (3:16)
- What were the safety findings of this study? (4:55)
- What have we learned about the need for long-term treatment with semaglutide? (6:54)
Disclosures: Clinical investigator for NovoNordisk, Boehringer Ingelheim and Astra Zeneca; speaker, consultant and shareholder for NovoNordisk; received speaker honoraria from WebMD/Medscape; grant recipient of Obesinov SARL.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ENDO 2021 (Virtual).
